COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)17/10/2025
-   
  BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways17/10/2025
-   
  24/7 Market News- Kraig Labs Spider Silk Poised to Lead the Sustainable Textile Revolution17/10/2025
-   
  Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week17/10/2025
-   
  Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show17/10/2025
-   
  WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage17/10/2025
-   
  Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 202517/10/2025
-   
  Protext Mobility, Inc. (OTC: TXTM) Announces Plans for Corporate Website Redesign and Investor Relations Suite to Enhance Transparency and Shareholder Engagement17/10/2025
-   
  Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 202517/10/2025
-   
  ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 202517/10/2025
-   
  AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors17/10/2025
-   
  TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 202517/10/2025
-   
  CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis17/10/2025
-   
  Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML17/10/2025
-   
  Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU17/10/2025
-   
  Tilray Brands Marks Seven Years of Cannabis Legalization in Canada with the #1 Market-Leading Position by Revenue and Pioneering Brands with Growing Market Share in the World’s Largest Federally Legal Cannabis Market17/10/2025
-   
  Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure17/10/2025
-   
  Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 202517/10/2025
-   
  Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting17/10/2025
Pages